机构：[1]Department of Radiation Oncology, Institut Bergoni�e, 33076 Bordeaux, France[2]Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, Unit�e Mixte de Recherche CNRS5822/IP2I, University of Lyon,Oullins 69921, France[3]Medical Oncology Department, Private Loire Hospital (HPL), Saint-Etienne, France[4]Centro Hospitalar Universitario do Algarve, 8000-386 Faro, Portugal[5]Department of Radiation Oncology, Hospital S�ırio-Liban^es, S~ao Paulo, Brazil[6]Division of Radiation Oncology, Department of Radiology and Oncology, Instituto do C^ancer do Estado de S~ao Paulo, Faculdade deMedicina da Universidade de S~ao Paulo, S~ao Paulo, Brazil[7]Unidad Funcional de Tumore de Cabeza y Cuello, Instituto de Oncolog�ıa Angel � H. Roffo Universidad de Buenos Aires, BuenosAires, Argentina[8]Medical Oncology Department, Catalan Institut of Oncology, 08916 Badalona, Spain and B-ARGO Group, IGTP, Badalona, Spain[9]National Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece[10]Division of Hematology-Oncology, Department of Medicine, University of California San Diego Health, Moores Cancer Center, La Jolla, CA,United States[11]Head and Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY, United States[12]Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu, Sichuan, China四川省肿瘤医院[13]Department of Radiation Oncology, Infertility and Reproductive Health Research Center, Shaid Behesti University of Medical Sciences,Teheran, Iran[14]Clinical, Molecular and Cellular Radiobiology Research Group, Instituto Nacional de Cancerologia, Bogota, Colombia[15]Department of Medical Oncology, North Hospital, University Hospital of Saint-Etienne, Saint-Etienne, 42270, France[16]Department of Radiotherapy, Universit�e Paris-Saclay, Gustave Roussy, 94805 Villejuif, France and INSERM, Radioth�erapie Mol�eculaire etInnovation Th�erapeutique, 94805 Villejuif, France
Emerging countries are currently facing an increasing burden of cancer while they do not have adequate prevention, monitoring, and research capabilities to tackle the disease. Cancer outcomes are influenced by several factors, including different cancer patterns, national cancer screening guidelines, current stage of disease, and access to quality care and treatments. Discrepancies in cancer care between emerging and developed countries require actions to achieve global health equity. The process of pioneering a sister relationship in the oncology field can thwart the global burden of cancer. The objective of such cooperation programs should include research and training programs, evidence-based oncology practice, and quality cancer. Building global connections will therefore be the novel approach to addressing the global burden of cancer.
第一作者机构：[1]Department of Radiation Oncology, Institut Bergoni�e, 33076 Bordeaux, France[2]Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, Unit�e Mixte de Recherche CNRS5822/IP2I, University of Lyon,Oullins 69921, France
通讯作者：
通讯机构：[15]Department of Medical Oncology, North Hospital, University Hospital of Saint-Etienne, Saint-Etienne, 42270, France[*1]Department of Medical Oncology, Cancerology and Hematology Institute, Saint-Etienne University Hospital,108 bis Avenue Albert Raimond, 42270 Saint Etienne, France
推荐引用方式(GB/T 7714)：
Magne Nicolas,Sotton Sandrine,Gomes Ana Varges,et al.Sister partnership to overcome the global burden of cancer[J].BRITISH JOURNAL OF RADIOLOGY.2024,97(1164):1891-1897.doi:10.1093/bjr/tqae179.
APA：
Magne, Nicolas,Sotton, Sandrine,Gomes, Ana Varges,Marta, Gustavo Nader,Giglio, Raul Eduardo...&Deutsch, Eric.(2024).Sister partnership to overcome the global burden of cancer.BRITISH JOURNAL OF RADIOLOGY,97,(1164)
MLA：
Magne, Nicolas,et al."Sister partnership to overcome the global burden of cancer".BRITISH JOURNAL OF RADIOLOGY 97..1164(2024):1891-1897
